| 1 |
33921947 | A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRASQ61R/K/L Mutant Melanoma (TraMel-WT). | 2021 Apr 22 |
1 |
| 2 |
32388065 | Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer. | 2020 Jun |
1 |
| 3 |
29112787 | Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition. | 2018 Jan |
2 |
| 4 |
29631033 | An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib. | 2018 Aug |
1 |
| 5 |
22389471 | Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. | 2012 Apr |
7 |